Skip to main content

Table 2 Change from baseline in trough FEV 1 (L) at Week 24 (intent-to-treat population)

From: Efficacy and safety of fluticasone furoate 100 μg and 200 μg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study

Trough FEV1(Week 24) FF 100 μg FF 200 μg
  (N = 108) (N = 111)
n 106 109
LS mean 2.271 2.347
LS mean change from baseline (SE) 0.208 (0.042) 0.284 (0.041)
Treatment difference vs. NA 0.077
FF 100 μg (95% CI) (-0.039, 0.192)
  1. Note: analysis performed using ANCOVA with covariates of baseline, region, sex, age and treatment. The last observation carried forward method was used to impute missing data.
  2. CI = confidence interval; FF = fluticasone furoate; LS = least squares; NA = not applicable; SE = standard error.